Pain Management After Functional Endoscopic SinuscopyPhase 2/3NCT07555821
Improving Postoperative Analgesia After Functional Endoscopic Surgery
A Phase 2/3 study testing Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine in people with Pain Management After Functional Endoscopic Sinuscopy, run by South Egypt Cancer Institute at 1 site in Egypt.
Trial summary
Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Pain Management After Functional Endoscopic Sinuscopy
- What is being tested?
- Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteEgypt
- Study dates
- 15 Apr 2026to 30 Oct 2026
- Phase
- Phase 2/3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Age 18 - 60 years
- ASA physical status I -II
- Patients scheduled for elective FESS
Who cannot join
- Allergy to drugs used
- Coagulopathy or anticoagulant therapy
- Severe cardiovascular, renal and hepatic disease
- Chronic opioid use Pregnancy
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Improving Postoperative Analgesia After Functional Endoscopic Surgery: Sphenopalatine Ganglion Block Versus Soaked Nasal Packing Using Bupivacaine and Dexmedetomidine
Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine
- Being tested
- Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sphenopalatine ganglion block (SPGB) with Bupivacaine and DexmedetomidineDrug
Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine
| Study group | Role | What they receive |
|---|---|---|
| group a | Experimental | Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine Receives: Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine |
| druop b | Experimental | Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine Receives: Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia
Numeric rating scale for pain will be assessed and recorded within the first 24 hours where 1 means the worst pain and 10 means no pain. Total rescue analgesia in 24 H when Numeric rating scale ≥ 4 was recorded and the first time when it was given will be recorded.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Apr 2026
- Study start15 Apr 2026 (estimated)
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pain Management After Functional Endoscopic SinuscopyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Lead sponsor
- South Egypt Cancer Institute
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Kamal Sayed, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07555821
- Sponsor's protocol ID
- 04-2026-300806
- Status last verified
- Apr 2026
- First submitted
- 14 Apr 2026
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Postoperative Analgesia After Functional Endoscopic Surgery: Sphenopalatine Ganglion Block Versus Soaked Nasal Packing Using Bupivacaine and Dexmedetomidine
- ClinicalTrials.gov ID
- NCT07555821
- Acronym / sponsor ID
- 04-2026-300806
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- South Egypt Cancer InstituteUniversity, hospital or other
- Study start
- 15 Apr 2026 (estimated)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 29 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Improving postoperative analgesia after functional endoscopic surgery: Sphenopalatine ganglion block versus soaked nasal packing using bupivacaine and dexmedetomidine
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| group a | Experimental | Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and DexmedetomidineSphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine |
| druop b | Experimental | Drug: Sphenopalatine ganglion block (SPGB) with Bupivacaine and DexmedetomidineSphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Age 18 - 60 years
- ASA physical status I -II
- Patients scheduled for elective FESS
Key exclusion criteria (4 listed)
- Allergy to drugs used
- Coagulopathy or anticoagulant therapy
- Severe cardiovascular, renal and hepatic disease
- Chronic opioid use Pregnancy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sphenopalatine ganglion block (SPGB) with Bupivacaine and DexmedetomidineSphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine | Drug | druop b, group a |
Primary outcome
effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia
Time frame: 6 months
Numeric rating scale for pain will be assessed and recorded within the first 24 hours where 1 means the worst pain and 10 means no pain. Total rescue analgesia in 24 H when Numeric rating scale ≥ 4 was recorded and the first time when it was given will be recorded.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Sphenopalatine ganglion block (SPGB) with Bupivacaine and Dexmedetomidine in people with Pain Management After Functional Endoscopic Sinuscopy, run by South Egypt Cancer Institute at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sara Mansour Mansour (1061092528 ext. 0020, saram@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
effectiveness of SPGB with bupivacaine and dexmedetomidine for postoperative analgesia (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.